Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

Thromboembolism in people with cancer still remains a major health problem and is a
leading cause of mortality after cancer itself, despite being a largely preventable disease. 1 …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial
workup, treatment, follow-up, and supportive care for patients with various plasma cell …

Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients
with cancer. Over the past 2 decades, enormous advances have been made in the …

Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …

In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and
lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable …

Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs
are at high risk of venous thromboembolism (VTE), but data are lacking from large …

Venous and arterial thromboembolism are prevalent, highly burdensome, and associated
with risk of worse outcomes for patients with cancer. Risk for venous thromboembolism …